LFMD · Lifemd, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50.16M | - | $60.17M | $62.22M | $65.70M | - | $53.39M | $50.66M | $44.14M | - |
| Cost of Revenue | $5.93M | - | $7.41M | $7.43M | $8.64M | - | $5.01M | $5.02M | $4.60M | - |
| Gross Profit | $44.24M | - | $52.76M | $54.79M | $57.05M | - | $48.38M | $45.64M | $39.54M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $15.18M | - | $16.59M | $17.57M | $17.06M | - | $18.93M | $18.52M | $15.31M | - |
| Total Operating Expenses | $53.17M | - | $54.73M | $55.69M | $54.51M | - | $53.07M | $51.94M | $45.72M | - |
| D&A | $289.5K | - | - | - | $162.6K | - | - | - | $65.9K | - |
| Operating Income | ($8.93M) | - | ($1.97M) | ($906.8K) | $2.54M | - | ($4.69M) | ($6.31M) | ($6.17M) | - |
| Interest Expense | ($56.5K) | - | $262.5K | $663.0K | $626.3K | - | $558.6K | $531.5K | $477.7K | - |
| Income Tax | - | - | $169.1K | - | - | - | $232.5K | - | - | - |
| Net Income | ($8.87M) | - | ($3.81M) | ($2.07M) | $1.38M | - | ($5.13M) | ($6.88M) | ($6.77M) | - |
| EPS - Basic | ($0.20) | - | ($0.13) | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.20) | - | ($0.13) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.95M | $36.79M | $35.00M | $36.23M | $34.39M | $35.00M | $37.59M | $35.70M | $35.11M | $33.15M |
| Accounts Receivable | $9.86M | $9.31M | $9.24M | $7.33M | $10.19M | $8.22M | $6.05M | $5.67M | $5.34M | $5.28M |
| Inventory | $3.18M | $2.77M | $3.43M | $3.25M | $2.97M | $2.80M | $2.65M | $2.06M | $2.37M | $2.76M |
| Accounts Payable | $21.65M | $14.15M | $19.55M | $24.29M | $15.68M | $16.01M | $15.87M | $15.05M | $12.40M | $11.08M |
| Current Assets | $51.70M | $51.83M | $41.09M | $49.03M | $49.97M | $48.73M | $48.66M | $45.07M | $44.41M | $42.60M |
| Total Assets | $70.12M | $70.41M | $65.98M | $73.56M | $73.61M | $72.46M | $72.56M | $63.82M | $61.46M | $58.48M |
| Current Liabilities | $49.59M | $41.57M | $56.66M | $63.53M | $60.90M | $60.26M | $58.95M | $51.65M | $44.68M | $34.78M |
| Long-term Debt | - | - | - | $15.90M | - | - | - | - | - | - |
| Total Liabilities | $55.09M | $47.25M | $62.62M | $73.18M | $74.01M | $76.51M | $78.51M | $65.88M | $60.16M | $52.91M |
| Stockholders' Equity | $15.04M | $23.16M | $1.31M | ($1.78M) | ($2.33M) | ($5.49M) | ($7.72M) | ($4.21M) | ($845.3K) | $3.51M |
| Retained Earnings | ($238.25M) | ($228.60M) | ($247.79M) | ($238.50M) | ($235.64M) | ($236.25M) | ($235.37M) | ($229.46M) | ($221.81M) | ($214.27M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $444.6K | - | - | - | $3.07M | - | - | - | $5.20M | - |
| Investing Cash Flow | ($2.06M) | - | - | - | ($2.87M) | - | - | - | ($2.19M) | - |
| Financing Cash Flow | ($696.0K) | - | - | - | ($812.6K) | - | - | - | ($1.05M) | - |
| CapEx | $105.2K | - | - | - | $122.2K | - | - | - | $175.6K | - |
| Free Cash Flow | $339.4K | - | - | - | $2.95M | - | - | - | $5.03M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 88.2% | - | 87.7% | 88.1% | 86.8% | - | 90.6% | 90.1% | 89.6% | - |
| Operating margin | -17.8% | - | -3.3% | -1.5% | 3.9% | - | -8.8% | -12.4% | -14.0% | - |
| EBITDA margin | -17.2% | - | - | - | 4.1% | - | - | - | -13.8% | - |
| Net margin | -17.7% | - | -6.3% | -3.3% | 2.1% | - | -9.6% | -13.6% | -15.3% | - |
| Free cash flow margin | 0.7% | - | - | - | 4.5% | - | - | - | 11.4% | - |
| FCF / Net income | -0.04 | - | - | - | 2.13 | - | - | - | -0.74 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 30.3% | - | 27.6% | 28.2% | 26.0% | - | 35.4% | 36.6% | 34.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.7% | - | -5.8% | -2.8% | 1.9% | - | -7.1% | -10.8% | -11.0% | - |
| Return on equity | -59.0% | - | -289.6% | 116.4% | -59.5% | - | 66.5% | 163.5% | 800.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.04 | 1.25 | 0.73 | 0.77 | 0.82 | 0.81 | 0.83 | 0.87 | 0.99 | 1.22 |
| Quick ratio | 0.98 | 1.18 | 0.66 | 0.72 | 0.77 | 0.76 | 0.78 | 0.83 | 0.94 | 1.15 |
| Cash ratio | 0.64 | 0.88 | 0.62 | 0.57 | 0.56 | 0.58 | 0.64 | 0.69 | 0.79 | 0.95 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | -8.92 | - | - | - | - | - | - |
| Debt / Assets | - | - | - | 0.22 | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 158.1x | - | -7.5x | -1.4x | 4.1x | - | -8.4x | -11.9x | -12.9x | - |
| Equity multiplier | 4.66 | 3.04 | 50.20 | -41.27 | -31.61 | -13.21 | -9.40 | -15.17 | -72.70 | 16.68 |
| Liabilities / Assets | 0.79 | 0.67 | 0.95 | 0.99 | 1.01 | 1.06 | 1.08 | 1.03 | 0.98 | 0.90 |
| Efficiency | ||||||||||
| Asset turnover | 0.72 | - | 0.91 | 0.85 | 0.89 | - | 0.74 | 0.79 | 0.72 | - |
| Inventory turnover | 1.87 | - | 2.16 | 2.29 | 2.91 | - | 1.90 | 2.44 | 1.94 | - |
| Days sales outstanding | 72d | - | 56d | 43d | 57d | - | 41d | 41d | 44d | - |
| Days inventory outstanding | 196d | - | 169d | 160d | 125d | - | 193d | 150d | 188d | - |
| Days payable outstanding | 1334d | - | 963d | 1193d | 662d | - | 1155d | 1093d | 983d | - |
| Cash conversion cycle | -1066d | - | -738d | -991d | -480d | - | -921d | -903d | -751d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 11.4x | - | 238.5x | - | - | - | - | - | - | - |
| P / S | 3.4x | - | 5.2x | 9.7x | 3.8x | - | 4.1x | 5.6x | 11.0x | - |
| EV / EBITDA | - | - | - | - | 78.9x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -23.6% | - | 12.7% | 22.8% | 48.8% | - | 38.3% | 40.9% | 33.3% | - |
| Revenue CAGR (3y) | 14.8% | - | 24.2% | 26.9% | 31.3% | - | 28.9% | 31.4% | 34.4% | - |
| Revenue CAGR (5y) | 22.5% | - | 40.5% | 46.9% | 72.5% | - | 76.4% | 79.8% | 74.9% | - |
| Gross profit growth (YoY) | -22.5% | - | 9.1% | 20.1% | 44.3% | - | 43.0% | 45.3% | 36.8% | - |
| Operating income growth (YoY) | - | - | 58.0% | 85.6% | - | - | -2.6% | -28.8% | -116.3% | - |
| Net income growth (YoY) | - | - | 25.8% | 69.8% | - | - | 16.2% | -2.1% | -68.9% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -88.5% | - | - | - | -41.4% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | 57.6% | -175.5% | - | 39.1% | 73.7% | 93.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$194.06M totalTelehealth Subscription Revenue$113.27M · 58.4%
Telehealth$80.79M · 41.6%
Peer comparison
Same SIC group: Services-Offices & Clinics of Doctors of Medicine
Comparing LifeMD against the 5 most active filers in the same SIC group.